MAGE-1 (278-286)

MAGE-1 (278-286) is a synthetic peptide corresponding to amino acids 278 through 286 of the Melanoma Antigen Gene-1 (MAGE-1) protein, a member of the cancer-testis antigen family. Recognized for its immunogenic properties and unique expression profile in various tumor cells, this peptide has become a valuable molecular tool in immunological research, epitope mapping, and T-cell recognition studies. The defined sequence enables precise investigation of antigen-specific immune responses, supporting the advancement of cancer immunology, peptide vaccine development, and cellular immunotherapy research.

Epitope mapping: MAGE-1 (278-286) is widely used in the identification and characterization of immunodominant epitopes recognized by cytotoxic T lymphocytes (CTLs). By serving as a defined antigenic determinant, the peptide enables researchers to dissect the precise interactions between T-cell receptors and tumor-associated antigens. This facilitates the study of antigen processing and presentation pathways, as well as the identification of key residues critical for immune recognition, thereby contributing valuable insights to tumor immunology.

T-cell activation assays: The peptide is instrumental in functional assays designed to assess the activation, proliferation, and cytolytic activity of antigen-specific T cells. When presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells, it can stimulate MAGE-1-specific CD8+ T cells in vitro. These assays are essential for evaluating immune responses to tumor antigens, optimizing immunotherapeutic strategies, and screening for T-cell receptor specificity and avidity.

Peptide-based vaccine research: As a well-characterized tumor-associated epitope, MAGE-1 (278-286) serves as a model antigen in the development and evaluation of peptide-based cancer vaccines. Its defined sequence allows for precise formulation and testing of vaccine candidates aimed at eliciting robust and specific anti-tumor immune responses. Studies utilizing this peptide contribute to the optimization of vaccine delivery systems, adjuvant selection, and immunization protocols targeting cancer-testis antigens.

Immunomonitoring: The peptide is frequently employed as a reference antigen in immunomonitoring protocols to track the frequency and functionality of MAGE-1-specific T cells in experimental systems. By using this defined sequence in ex vivo assays such as ELISPOT or intracellular cytokine staining, researchers can quantify antigen-specific T-cell responses, monitor immune dynamics during experimental interventions, and evaluate the efficacy of immunomodulatory agents.

Peptide-MHC binding studies: MAGE-1 (278-286) provides a valuable substrate for investigating the binding affinity and stability of peptide-MHC class I complexes. Such studies are crucial for understanding the molecular determinants of antigen presentation, refining peptide selection for immunotherapeutic applications, and developing high-affinity ligands for use in diagnostic or research settings. The peptide's sequence specificity supports detailed biophysical and structural analyses of MHC-peptide interactions, advancing fundamental knowledge in antigen processing and immune recognition.

1. Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors

2. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function

3. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists

4. Immune responses to peptides containing homocitrulline or citrulline in the DR4-transgenic mouse model of rheumatoid arthritis

5. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy